Fountain Life, a longevity-focused health tech company co-founded by motivational speaker Tony Robbins and futurist Peter Diamandis, has closed an $18 million funding round to expand its personalized preventive health and aging intervention services. The investment, led by venture capital firm Khosla Ventures with participation from existing backers including Founders Fund and individual investors in the health tech space, will support the launch of new clinics, the development of AI-driven health analytics tools, and broader access to its “precision longevity” programs—all aimed at helping individuals detect age-related health risks early and extend their healthy lifespans.
Launched in 2023, Fountain Life differentiates itself from traditional healthcare providers by centering on proactive longevity care rather than reactive treatment. Instead of waiting for patients to develop illnesses, the company offers comprehensive assessments (including advanced blood work, full-body MRI scans, epigenetic aging tests, and metabolic analysis) to identify subtle markers of aging and chronic disease risk. It then pairs clients with personalized plans—combining nutrition, exercise, supplements, and cutting-edge interventions like peptide therapies or senolytics (drugs that clear aging cells)—to slow or reverse age-related decline. For Robbins and Diamandis, the company’s mission is to make “longevity science accessible to more people, not just the elite.”
The Vision Behind Fountain Life: From “Sick Care” to “Longevity Care”
Diamandis, a serial entrepreneur best known for founding the XPRIZE Foundation and space tech firms like Planetary Resources, has long advocated for leveraging technology to extend human healthspan. Robbins, a globally recognized life and business strategist, brings expertise in consumer engagement and scaling mission-driven brands. Together, they say Fountain Life was born from a shared frustration with the traditional healthcare system’s focus on treating disease rather than preventing it.
“Right now, 80% of healthcare spending goes to treating chronic illness—most of which is preventable with early detection and lifestyle changes,” Diamandis explained in a post-funding interview. “Fountain Life flips that script. We use the latest science and AI to give people a ‘roadmap’ of their biological age—not just their chronological age—and then help them rewrite that roadmap. It’s not about living forever; it’s about living longer, healthier lives where you can still pursue the things you love.”
Robbins added that the company’s approach is rooted in accessibility. “For too long, longevity treatments have been limited to billionaires who can afford $100,000-a-year concierge care,” he said. “We’re building Fountain Life to serve a broader audience—from busy professionals to retirees—by making our assessments and plans more affordable and convenient. This funding will help us bring that vision to more communities.”
How Fountain Life’s Model Works
Fountain Life’s core offering is its Longevity Membership, which includes:
- Comprehensive Biological Assessment: A full day of testing at one of the company’s clinics, including:
- Epigenetic testing to measure biological age (using DNA methylation analysis, a gold standard for aging research).
- Full-body MRI and low-dose CT scans to detect early signs of cancer, heart disease, or organ decline.
- Advanced blood panels that track biomarkers for inflammation, insulin resistance, and nutrient deficiencies—key drivers of aging.
- AI-Powered Health Insights: A personalized “Longevity Report” generated by the company’s proprietary AI tool, which analyzes test results to identify high-risk areas (e.g., “Your epigenetic age is 5 years older than your chronological age due to chronic stress”) and prioritize interventions.
- Dedicated Care Team: A team of longevity specialists (doctors, nutritionists, exercise physiologists) who develop and monitor a personalized plan, with regular check-ins and adjustments based on progress.
- Access to Cutting-Edge Interventions: For eligible clients, access to treatments like senolytics, NAD+ therapy (a coenzyme linked to energy production and DNA repair), or personalized peptide protocols—all approved by the company’s medical advisory board, which includes leading aging researchers from Stanford and Harvard.
Early data from Fountain Life’s existing clinics (currently in Los Angeles, Austin, and New York) shows promising results: 78% of members reported a reduction in biological age after 12 months, and 65% saw improvements in key biomarkers like cholesterol and blood sugar. A 45-year-old tech executive who joined the program last year said, “My chronological age is 45, but my biological age dropped from 48 to 42. More importantly, I have more energy, and my doctor said my heart health is now that of a 38-year-old. It’s not just numbers—it’s how I feel every day.”
Why Investors Are Backing Longevity Tech
The $18 million round underscores growing investor enthusiasm for the longevity sector, which is projected to reach $600 billion globally by 2030, according to Grand View Research. Khosla Ventures, which led the investment, has a history of backing breakthrough health tech firms (including CRISPR Therapeutics and Unity Biotechnology) and sees Fountain Life as a leader in making longevity science mainstream.
“Longevity is no longer a niche ‘biohacking’ trend—it’s a massive consumer health opportunity,” said Vinod Khosla, founder of Khosla Ventures. “What sets Fountain Life apart is its combination of rigorous science, consumer-friendly design, and a mission to democratize access. Tony and Peter have built a team that understands both the science and the human side of longevity—how to motivate people to stick with healthy habits over time. That’s the secret sauce for success in this space.”
Existing investors also highlighted the company’s scalable model. “Fountain Life isn’t just a chain of clinics—it’s a tech-enabled platform that can integrate new research and AI tools as the science evolves,” said a partner at Founders Fund, which participated in the round. “As we learn more about aging, their model can adapt quickly—something that traditional healthcare providers can’t do.”
What’s Next for Fountain Life
With the new funding, Fountain Life plans to:
- Expand Clinic Footprint: Open 10 new clinics in major U.S. cities (including Chicago, Miami, and Seattle) by the end of 2026, with plans to enter international markets (starting with London and Dubai) in 2027.
- Enhance AI Tools: Invest in upgrading its AI platform to include real-time monitoring (e.g., integrating with wearable devices like Apple Watch to track sleep and activity) and predictive modeling (e.g., “Your current diet increases your risk of metabolic decline by 30%—here’s how to adjust”).
- Launch a Lower-Cost Membership Tier: Introduce a “Digital Longevity Plan” for $199/month (compared to its current $499/month in-clinic membership) that includes remote assessments, AI-generated plans, and virtual check-ins—making longevity care accessible to a wider audience.
Diamandis and Robbins are also focused on partnering with employers to offer Fountain Life as a workplace benefit, citing data that shows preventive health programs reduce healthcare costs and improve employee productivity. “We’re in talks with several Fortune 500 companies to make our memberships available to their teams,” Robbins said. “Imagine a world where your employer invests in your long-term health, not just your next doctor’s visit. That’s the future we’re building.”
As the global population ages and consumers become more proactive about their health, Fountain Life’s $18 million funding round signals a shift in how the world thinks about aging—from an inevitable decline to a process that can be managed, and even reversed, with the right tools and support. For Robbins and Diamandis, this is just the beginning: “We want Fountain Life to be the brand that makes longevity care as common as going to the gym,” Diamandis said. “This funding gets us one step closer to that goal.”